SEC Form 4Coverage since Aug 7, 2025Open-market trades only
$ELVN insider trading
Over the last 12 months, Enliven Therapeutics insiders reported no purchases and 40 sales totaling $76.4M across SEC Form 4 filings. 92% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $76.4M 40 events
- Events · 12m
- 40 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 92% of events, not dollars
Side
Price · $ELVN · 3Mvia TradingView
Top insiders · 12m
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER9× · $5.0M
Collins Helen LouiseCHIEF MEDICAL OFFICER8× · $4.9M
Kintz SamuelPRESIDENT AND CEO5× · $785K
Hohl BenjaminCHIEF FINANCIAL OFFICER5× · $1.3M
Patel AnishCHIEF OPERATING OFFICER5× · $1.9M
All insider trades
44 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 6,018 | $58.58 | $353K | -13.1% | plan · 2 tranches |
| Aug 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $58.59 | $293K | -16.7% | plan · 2 tranches |
| Aug 4, 2026 | Derynck Mika KD | ▼ Sale | 158,795 | $60.21 | $9.6M | -100% | plan |
| Jul 17, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 6,018 | $52.64 | $317K | -11.6% | plan · 5 tranches |
| Jul 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $52.67 | $263K | -16.7% | plan · 5 tranches |
| Jul 6, 2026 | Kunkel Lori AnneD | ▼ Sale | 10,000 | $50.49 | $505K | -19.3% | plan · 2 tranches |
| Jun 22, 2026 | ORBIMED ADVISORS LLC10% | ▼ Sale | 860,123 | $45.36 | $39.0M | -11.6% | 4 tranches · indirect |
| Jun 17, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 6,018 | $43.8 | $264K | -10.6% | plan · 3 tranches |
| Jun 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $43.8 | $219K | -16.7% | plan · 3 tranches |
| Jun 15, 2026 | ORBIMED ADVISORS LLC10% | ▼ Sale | 281,408 | $45.02 | $12.7M | -3.7% | 2 tranches · indirect |
| Jun 5, 2026 | Kunkel Lori AnneD | ▼ Sale | 10,000 | $34.54 | $345K | -16.2% | plan · 3 tranches |
| Apr 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $47.67 | $238K | -16.7% | plan · 3 tranches |
| Mar 25, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 40,000 | $35.1 | $1.4M | -61.5% | plan |
| Mar 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 5,000 | $27.76 | $139K | -16.7% | plan |
| Mar 10, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 40,000 | $30.07 | $1.2M | -61.5% | plan · 2 tranches |
| Mar 6, 2026 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 10,000 | $29.58 | $296K | -16.4% | — |
| Feb 17, 2026 | Collins Helen LouiseCHIEF MEDICAL OFFICER · O | ▼ Sale | 45,000 | $26.17 | $1.2M | -64.3% | plan |
| Feb 17, 2026 | Heyman Richard A.D | ▼ Sale | 1,230 | $26.18 | $32K | -5.2% | plan · indirect |
| Feb 6, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 5,000 | $29.04 | $145K | -0.7% | plan · indirect |
| Jan 20, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 20,000 | $26.75 | $535K | -2.6% | plan · 2 tranches · indirect |
| Jan 20, 2026 | Heyman Richard A.D | ▼ Sale | 1,230 | $26.75 | $33K | -4.9% | plan · 2 tranches · indirect |
| Jan 9, 2026 | Patel AnishCHIEF OPERATING OFFICER · O | ▼ Sale | 48,300 | $27.99 | $1.4M | -18.3% | plan · 2 tranches · indirect |
| Jan 9, 2026 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 132,500 | $26.23 | $3.5M | -14.8% | plan · 4 tranches · indirect |
| Jan 9, 2026 | Heyman Richard A.D | ▼ Sale | 13,920 | $25.02 | $348K | -35.7% | plan · 3 tranches · indirect |
| Dec 19, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 5,000 | $16.84 | $84K | -0.6% | plan · indirect |
| Dec 8, 2025 | Patel AnishCHIEF OPERATING OFFICER · O | ▼ Sale | 6,663 | $21.02 | $140K | -2.5% | plan · 2 tranches · indirect |
| Nov 19, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 12,500 | $22.33 | $279K | -1.4% | plan · 2 tranches · indirect |
| Nov 17, 2025 | Kintz SamuelPRESIDENT AND CEO · O·D | ▼ Sale | 12,500 | $21.82 | $273K | -1.4% | plan · indirect |
| Nov 7, 2025 | Patel AnishCHIEF OPERATING OFFICER · O | ▼ Sale | 6,667 | $17.4 | $116K | -2.4% | plan · 2 tranches · indirect |
| Oct 20, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 12,500 | $22.08 | $276K | -1.3% | plan · indirect |
| Oct 17, 2025 | Kintz SamuelPRESIDENT AND CEO · O·D | ▼ Sale | 12,500 | $21.33 | $267K | -1.4% | plan · indirect |
| Oct 7, 2025 | Patel AnishCHIEF OPERATING OFFICER · O | ▼ Sale | 6,667 | $20.1 | $134K | -2.4% | plan · indirect |
| Sep 29, 2025 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 3,250 | $20.4 | $66K | -12.4% | plan |
| Sep 26, 2025 | Kintz SamuelPRESIDENT AND CEO · O·D | ▼ Sale | 3,700 | $20.06 | $74K | -0.4% | plan · indirect |
| Sep 26, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 4,000 | $20.25 | $81K | -0.4% | plan · indirect |
| Sep 23, 2025 | Kintz SamuelPRESIDENT AND CEO · O·D | ▼ Sale | 2,800 | $20.03 | $56K | -0.3% | plan · indirect |
| Sep 23, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 1,500 | $20.03 | $30K | -0.2% | plan · indirect |
| Sep 19, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 7,000 | $19.39 | $136K | -0.7% | plan · 2 tranches · indirect |
| Sep 19, 2025 | Kintz SamuelPRESIDENT AND CEO · O·D | ▼ Sale | 6,000 | $19.29 | $116K | -0.6% | plan · 2 tranches · indirect |
| Sep 8, 2025 | Patel AnishCHIEF OPERATING OFFICER · O | ▼ Sale | 6,667 | $20.24 | $135K | -2.3% | plan · indirect |
| Aug 27, 2025 | Hohl BenjaminCHIEF FINANCIAL OFFICER · O | ▼ Sale | 3,250 | $20.63 | $67K | -12.4% | plan |
| Aug 21, 2025 | Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER · O | ▼ Sale | 12,500 | $19.86 | $248K | -1.3% | plan · 2 tranches · indirect |
| Aug 19, 2025 | Kintz SamuelPRESIDENT AND CEO · O·D | ▼ Sale | 10,983 | $20.02 | $220K | -1.2% | plan · 2 tranches · indirect |
| Aug 7, 2025 | Patel AnishCHIEF OPERATING OFFICER · O | ▼ Sale | 6,667 | $18.24 | $122K | -2.2% | plan · 2 tranches · indirect |
Every $ELVN filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Enliven Therapeutics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ELVN feed.